rituximab,obinutuzumab
biogen,roche
[]
townsend - 8y fu gallium, obi-chemo v r-chemo frontline fl (with maintenance)
- 23% reduction in pfs event
- prolonged ttnt
- no os benefit
- no additional safety data (some inc risk infection)
- ?less benefit low risk
benefit maintained in terms of pfs but soc?
#eha2022 
Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Past chair of UK Hodgkin and T-cell study groups.